Friday, October 30, 2026 · Edition updated 6:00 AM ETFRI, OCT 30 · 6 AM ET editionNext edition in Next --:--:--

Senolytic drug reduced skin scarring after radiation in mice

A study · International journal of radiation oncology, biology, physics · Oct 24, 2026

What this means

Researchers studied how radiation causes skin to stiffen and scar. They found a loop between aging cells and immune cells that seems to drive it. The drug ABT-263 reduced scarring in these mice, but this does not show it works in people.

Plain-English summary written by an AI model from the abstract. The original is below.

Tested inCells in a lab
Who it was tested in
Mice, plus cells grown in a lab dish
Kind of research
A study

The science

Original title
A senescence-driven fibroblast-macrophage feed-forward circuit promotes radiation induced cutaneous fibrosis.
Authors
Chung EJ, Kc S, Kwon S et al.
Journal
International journal of radiation oncology, biology, physics
Published
Oct 24, 2026
Study type
Study

Abstract

Background

Therapeutic radiation for superficial tumors may cause cutaneous fibrosis, a late side effect with limited treatment options. Here, we investigated the underlying mechanisms driving radiation-induced cutaneous fibrosis.

What they did

C3H/HeN mice received 35 Gy unilateral hind limb irradiation. Cutaneous tissues from irradiated and contralateral unirradiated legs were analyzed by spatial whole transcriptome profiling using the GeoMx Digital Spatial Profiler platform. Beginning at 5 weeks after irradiation, mice received the senolytic agent ABT-263 (50 mg/kg/day) or vehicle (n ≥ 10/group) by oral gavage (5 consecutive days followed by 2-week rest for 3 cycles). Hind limb contracture was assessed at 150 days after irradiation. Senescence and macrophage markers were evaluated by immunohistochemistry and quantitative PCR. Cellular senescence and senescence-associated secretory phenotype (SASP) factors were evaluated in irradiated fibroblasts and their culture media using senescence-associated β-galactosidase activity assays and multiplex immunoassays. The senolytic activity of ABT-263 in irradiated primary fibroblasts and effects of ABT-263 on primary macrophage cultures were evaluated in vitro.

What they found

Spatial whole-transcriptomic analysis of irradiated murine dermis identified expression patterns consistent with macrophage activation, extracellular matrix remodeling, and a senescence-associated secretory phenotype (SASP)-rich environment. In vitro studies identified that the irradiated fibroblast-derived SASP induced a senescent phenotype in unirradiated fibroblasts and macrophages. SASP-induced senescent-like macrophages acquired a CD206+ profibrotic phenotype and in concert with activated fibroblasts, initiated a feed-forward loop amplifying IL-6 and collagen production. SASP exposure increased expression of Bcl-2 family proteins in macrophages and fibroblasts, rendering both populations susceptible to clearance by the senolytic agent ABT-263. In vivo, ABT-263 effectively mitigated radiation-induced dermal fibrosis, depleted senescent fibroblasts and CD206⁺ macrophages, and reduced IL-6 expression Our findings identify senescence-driven reciprocal macrophage-fibroblast interactions as key mediators of cutaneous fibrosis and demonstrate the therapeutic potential of senolytic interventions for treating late radiation-induced skin injury.

The authors' abstract, grouped under plain headings from its own section labels.

Read it on PubMed ↗

Chung EJ, Kc S, Kwon S et al. A senescence-driven fibroblast-macrophage feed-forward circuit promotes radiation induced cutaneous fibrosis. International journal of radiation oncology, biology, physics. 2026. doi:10.1016/j.ijrobp.2026.10.013. PMID: 42925940. https://pubmed.ncbi.nlm.nih.gov/42925940/

Related research

Study · JACS Au · Oct 29, 2026

New fluorescent sensor detects cells aging from cancer and lung drugs

Researchers built a glowing probe that lights up only in certain aged cells. It may help scientists track these cells in living animals, but this is early lab work.

Study · Neuro-oncology · Oct 29, 2026

Mixing a senescence-clearing drug with trametinib slowed glioma regrowth in mice

Researchers found a drug combination that cleared aging-like tumour cells in mice and slowed regrowth. This does not show the combination would work the same way in children.

AnimalsStudy · Molecular metabolism · Oct 29, 2026

A vaccine-style treatment in mice eased diabetes signs and aged cell markers

Mice given a treatment aimed at a virus-like gene showed less weight gain and better blood sugar control. This study was in mice and cells, so it does not show the same would happen in people.

Summary of earlier studiesReview · Aging cell · Oct 28, 2026

Aging cells that support stem cells may disrupt them through chemical signals

This is a review that pulls together older and newer studies. It proposes a model, but it does not show that the model is true.

Preprint · bioRxiv · Oct 28, 2026

Cx43 protein may boost breast cancer drug response in lab tests

Researchers studied a protein called Cx43 that helps cells talk to each other. They found it may help a breast cancer drug slow tumor growth. This early work is not yet checked by other scientists, so it does not show this would help people.

PeopleClinical trial · American journal of physiology. Renal physiology · Oct 26, 2026

Home exercise may change muscle in people with kidney disease

A small trial found changes in muscle blood vessels and fewer fibrosis-linked cells after 12 weeks of home exercise. Only 25 people took part, so this does not prove the exercise caused lasting muscle benefits.

See all research on Senolytics →

Report a problem